The Promise and Peril of Anti-Amyloid Drugs for Alzheimer’s Disease: A Landmark Review Casts Doubt on Clinical Efficacy and Highlights Safety Concerns
A comprehensive and influential Cochrane review has delivered a significant blow to the long-held therapeutic strategy targeting amyloid beta proteins in the brain for Alzheimer’s disease, concluding that these drugs…







